CA3150316A1 - Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires - Google Patents

Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires Download PDF

Info

Publication number
CA3150316A1
CA3150316A1 CA3150316A CA3150316A CA3150316A1 CA 3150316 A1 CA3150316 A1 CA 3150316A1 CA 3150316 A CA3150316 A CA 3150316A CA 3150316 A CA3150316 A CA 3150316A CA 3150316 A1 CA3150316 A1 CA 3150316A1
Authority
CA
Canada
Prior art keywords
bispecific compound
optionally substituted
cancer
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150316A
Other languages
English (en)
Inventor
Nathanael S. Gray
Jinhua Wang
Fleur Marcia FERGUSON
Jie Jiang
Inchul YOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3150316A1 publication Critical patent/CA3150316A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés bispécifiques (agents de dégradation) qui ciblent l'ERK5 à des fins de dégradation. L'invention concerne également des compositions pharmaceutiques contenant les agents de dégradation et des procédés d'utilisation desdits composés pour traiter le cancer et les maladies inflammatoires.
CA3150316A 2019-09-27 2020-09-24 Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires Pending CA3150316A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907377P 2019-09-27 2019-09-27
US62/907,377 2019-09-27
PCT/US2020/052371 WO2021061894A1 (fr) 2019-09-27 2020-09-24 Agents de dégradation de l'erk5 utilisés comme agents thérapeutiques dans le cancer et les maladies inflammatoires

Publications (1)

Publication Number Publication Date
CA3150316A1 true CA3150316A1 (fr) 2021-04-01

Family

ID=75166154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150316A Pending CA3150316A1 (fr) 2019-09-27 2020-09-24 Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires

Country Status (5)

Country Link
US (1) US20220378919A1 (fr)
EP (1) EP4034132A4 (fr)
AU (1) AU2020356484A1 (fr)
CA (1) CA3150316A1 (fr)
WO (1) WO2021061894A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078350A1 (fr) * 2020-10-14 2022-04-21 Ranok Therapeutics (Hangzhou) Co. Ltd. Méthodes et compositions pour la dégradation ciblée de protéines
KR102604801B1 (ko) 2021-08-10 2023-11-22 (주) 업테라 신규 plk1 분해 유도 화합물
WO2023044482A1 (fr) * 2021-09-20 2023-03-23 Dana-Farber Cancer Institute, Inc. Agents de dégradation erk5 et leurs utilisations
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680757A1 (fr) * 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Pyrimidodiazepines substituees utiles en tant qu'inhibiteurs de plk1
CA2700979C (fr) * 2007-09-28 2017-06-20 Cyclacel Limited Derives de pyrimidine comme inhibiteurs de proteine kinases
EP3255047B1 (fr) * 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Composés d'échafaudage de kinase pyrimido-diazépinone et procédés de traitement de troubles
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2017007612A1 (fr) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
US20190374657A1 (en) * 2017-02-08 2019-12-12 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1

Also Published As

Publication number Publication date
US20220378919A1 (en) 2022-12-01
WO2021061894A1 (fr) 2021-04-01
AU2020356484A1 (en) 2022-03-17
EP4034132A4 (fr) 2023-10-11
EP4034132A1 (fr) 2022-08-03

Similar Documents

Publication Publication Date Title
US11530219B2 (en) Ligands to cereblon (CRBN)
CA3150316A1 (fr) Agents de degradation de l'erk5 utilises comme agents therapeutiques dans le cancer et les maladies inflammatoires
CA3093405A1 (fr) Agents de degradation a petites molecules de polybromo-1 (pbrm1)
US20230158157A1 (en) Potent and selective degraders of alk
US20220177466A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
AU2019294836A2 (en) Bispecific degraders
EP3813834A1 (fr) Nouveaux modulateurs du crbn
EP3856192A1 (fr) Agents de dégradation ciblant l'alk et leurs utilisations thérapeutiques
EP3952863A1 (fr) Agents de dégradation du récepteur 2 du facteur de croissance des fibroblastes (fgfr2)
WO2023288305A1 (fr) Agents de dégradation de la kinase dépendante de la cycline 4/6 (cdk4/6) et ikzf2 (helios) à petites molécules et leurs procédés d'utilisation
AU2020379812A1 (en) Selective dual histone deacetylase 6/8 (HDAC6/8) degraders and methods of use thereof
US20220033402A1 (en) Macrocyclic inhibitors of alk, trka, trkb, and ros1
WO2023044482A1 (fr) Agents de dégradation erk5 et leurs utilisations
EP4132514A1 (fr) Agents de dégradation de l'arginine méthyltransférase 5 (prmt5) et leurs utilisations
WO2022140554A1 (fr) Agents de dégradation à petites molécules de phosphatidylinositol-5-phosphate 4-kinase de type 2 et leurs utilisations